ESAM Reduces Anti-HER2 Therapy Sensitivity in Breast Cancer via mTOR Activation
Elevated ESAM expression promotes resistance to anti-HER2 therapy in HER2-positive breast cancer by stabilizing Calnexin and activating the mTOR pathway.
Elevated ESAM expression promotes resistance to anti-HER2 therapy in HER2-positive breast cancer by stabilizing Calnexin and activating the mTOR pathway.
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.